The role of transperineal MRI/TRUS fusion puncture in the diagnosis of prostate cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049386

Enrollment

Unknown

Registered

2021-08-01

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Experimental group:Transperineal prostate MRI/TRUS fusion puncture

Control group:System puncture

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Abnormal levels of prostate specific antigen (PSA); 2.Consent to a needle biopsy of the prostate; 3.The PI-RADS score is greater than 3.

Exclusion criteria

Exclusion criteria: Prostate needle biopsy has been performed in the last 3 months.

Design outcomes

Primary

Measure	Time frame
Prostate cancer detection rate;	—

Secondary

Measure	Time frame
Complication occurrence rate;	—

Countries

China

Contacts

Public ContactGao Fei

The First Affiliated Hospital of Chongqing Medical University

gaofei667@yahoo.com+86 13608356433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026